JP2015535263A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015535263A5 JP2015535263A5 JP2015539998A JP2015539998A JP2015535263A5 JP 2015535263 A5 JP2015535263 A5 JP 2015535263A5 JP 2015539998 A JP2015539998 A JP 2015539998A JP 2015539998 A JP2015539998 A JP 2015539998A JP 2015535263 A5 JP2015535263 A5 JP 2015535263A5
- Authority
- JP
- Japan
- Prior art keywords
- mass
- rhdl
- formulation
- apolipoprotein
- rhdl formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 33
- 238000009472 formulation Methods 0.000 claims 32
- 239000003381 stabilizer Substances 0.000 claims 13
- 102000007592 Apolipoproteins Human genes 0.000 claims 12
- 108010071619 Apolipoproteins Proteins 0.000 claims 12
- 150000002632 lipids Chemical class 0.000 claims 9
- 229930006000 Sucrose Natural products 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000005720 sucrose Substances 0.000 claims 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 3
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 2
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 2
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 1
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010020961 Hypocholesterolaemia Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261721771P | 2012-11-02 | 2012-11-02 | |
| US61/721,771 | 2012-11-02 | ||
| EP13153903 | 2013-02-04 | ||
| EP13153903.3 | 2013-02-04 | ||
| US13/803,863 | 2013-03-14 | ||
| US13/803,863 US9125943B2 (en) | 2012-11-02 | 2013-03-14 | Reconstituted HDL formulation |
| AU2013205684A AU2013205684B2 (en) | 2012-11-02 | 2013-04-10 | Reconstituted hdl formulation |
| AU2013205684 | 2013-04-10 | ||
| PCT/AU2013/001260 WO2014066943A1 (en) | 2012-11-02 | 2013-10-31 | Reconstituted hdl formulation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015535263A JP2015535263A (ja) | 2015-12-10 |
| JP2015535263A5 true JP2015535263A5 (enExample) | 2016-12-08 |
| JP6340372B2 JP6340372B2 (ja) | 2018-06-06 |
Family
ID=47665977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539998A Active JP6340372B2 (ja) | 2012-11-02 | 2013-10-31 | 再構成されたｈｄｌ製剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US9125943B2 (enExample) |
| EP (2) | EP2916857B1 (enExample) |
| JP (1) | JP6340372B2 (enExample) |
| KR (1) | KR102263810B1 (enExample) |
| CN (2) | CN104755096B (enExample) |
| AU (1) | AU2013205684B2 (enExample) |
| BR (1) | BR112015009748B1 (enExample) |
| CA (1) | CA2889785C (enExample) |
| IL (1) | IL238504B (enExample) |
| MX (1) | MX364587B (enExample) |
| NZ (1) | NZ631131A (enExample) |
| PL (1) | PL2916857T3 (enExample) |
| RU (1) | RU2669568C2 (enExample) |
| SG (1) | SG11201503083UA (enExample) |
| WO (1) | WO2014066943A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3178481T3 (en) | 2010-06-30 | 2019-04-08 | Csl Ltd | FORMULATION WITH RECONSTITUTED HIGH DENSITY LIPOPROTEIN AND PROCEDURE FOR PREPARING THEREOF |
| US9125943B2 (en) * | 2012-11-02 | 2015-09-08 | Csl Limited | Reconstituted HDL formulation |
| DK3004160T3 (da) | 2013-06-05 | 2023-01-23 | Csl Ltd | Fremgangsmåde til fremstilling af apolipoprotein a-i (apo a-i) |
| AU2014305646C1 (en) | 2013-08-08 | 2019-01-17 | Csl Limited | Contaminant removal method |
| WO2018019911A1 (en) | 2016-07-27 | 2018-02-01 | Hartis-Pharma Sarl | Therapeutic combinations to treat red blood cell disorders |
| IL266428B2 (en) * | 2016-11-10 | 2024-12-01 | Csl Ltd | High-density lipoprotein (HDL) is restored to treat myocardial infarction |
| CN112546201A (zh) * | 2019-09-26 | 2021-03-26 | 中国科学院生物物理研究所 | 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用 |
| WO2025185021A1 (zh) * | 2024-03-05 | 2025-09-12 | 维康平生(北京)生物科技有限公司 | 一种脂肪体的冷冻干燥方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1335077C (en) * | 1988-02-08 | 1995-04-04 | Henri Isliker | Process for the manufacture of apolipoproteins from human blood plasma or serum |
| US5652339A (en) | 1993-12-31 | 1997-07-29 | Rotkreuzstiftung Zentrallaboratorium | Method of producing reconstituted lipoproteins |
| MXPA04002848A (es) | 2001-09-28 | 2005-06-06 | Esperion Therapeutics Inc | Prevencion y tratamiento de restenosis por administracion local de medicamento. |
| US20040067873A1 (en) | 2002-05-17 | 2004-04-08 | Dasseux Jean-Louis H. | Method of treating dyslipidemic disorders |
| NZ537006A (en) | 2002-05-17 | 2008-01-31 | Esperion Therapeutics Inc | The use of apolipoprotein A-I Milano, for the manufacture ofa composition for treating preventing or reducing ischemic reperfusion injury in a tissue or organ |
| PE20050438A1 (es) | 2003-10-20 | 2005-06-14 | Esperion Therapeutics Inc | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos |
| US20070254832A1 (en) * | 2006-02-17 | 2007-11-01 | Pressler Milton L | Methods for the treatment of macular degeneration and related eye conditions |
| KR100992488B1 (ko) | 2006-12-29 | 2010-11-05 | 주식회사 녹십자 | ＡｐｏＡ-Ｉ의 정제방법 및 정제된ＡｐｏＡ-Ｉ을 이용한재구축 ＨＤＬ의 생산 방법 |
| WO2009025754A2 (en) | 2007-08-17 | 2009-02-26 | Csl Behring Gmbh | Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i |
| WO2010057203A2 (en) | 2008-11-17 | 2010-05-20 | The Board Of Regents Of The University Of Texas System | Hdl particles for delivery of nucleic acids |
| DK3178481T3 (en) * | 2010-06-30 | 2019-04-08 | Csl Ltd | FORMULATION WITH RECONSTITUTED HIGH DENSITY LIPOPROTEIN AND PROCEDURE FOR PREPARING THEREOF |
| PT2673296T (pt) * | 2011-02-07 | 2019-01-31 | Cerenis Therapeutics Holding Sa | Complexos de lipoproteínas e sua fabricação e utilização |
| US9125943B2 (en) | 2012-11-02 | 2015-09-08 | Csl Limited | Reconstituted HDL formulation |
-
2013
- 2013-03-14 US US13/803,863 patent/US9125943B2/en active Active
- 2013-04-10 AU AU2013205684A patent/AU2013205684B2/en active Active
- 2013-10-31 SG SG11201503083UA patent/SG11201503083UA/en unknown
- 2013-10-31 JP JP2015539998A patent/JP6340372B2/ja active Active
- 2013-10-31 WO PCT/AU2013/001260 patent/WO2014066943A1/en not_active Ceased
- 2013-10-31 EP EP13851610.9A patent/EP2916857B1/en active Active
- 2013-10-31 NZ NZ631131A patent/NZ631131A/en unknown
- 2013-10-31 EP EP19151328.2A patent/EP3502131A1/en active Pending
- 2013-10-31 CA CA2889785A patent/CA2889785C/en active Active
- 2013-10-31 CN CN201380057007.0A patent/CN104755096B/zh active Active
- 2013-10-31 PL PL13851610T patent/PL2916857T3/pl unknown
- 2013-10-31 CN CN201711141045.0A patent/CN108057023B/zh active Active
- 2013-10-31 KR KR1020157014530A patent/KR102263810B1/ko active Active
- 2013-10-31 RU RU2015120808A patent/RU2669568C2/ru active
- 2013-10-31 BR BR112015009748-0A patent/BR112015009748B1/pt active IP Right Grant
- 2013-10-31 US US14/439,094 patent/US9925236B2/en active Active
- 2013-10-31 MX MX2015004546A patent/MX364587B/es active IP Right Grant
-
2015
- 2015-04-28 IL IL238504A patent/IL238504B/en active IP Right Grant
-
2018
- 2018-02-12 US US15/894,397 patent/US10603355B2/en active Active
-
2020
- 2020-03-23 US US16/826,585 patent/US11464828B2/en active Active
-
2022
- 2022-09-02 US US17/902,580 patent/US11957731B2/en active Active
-
2024
- 2024-04-12 US US18/634,576 patent/US20250099537A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015120808A (ru) | Восстанавливаемый состав hdl | |
| KR101475419B1 (ko) | 하전된 지단백질 복합체 및 그의 용도 | |
| Wang et al. | ABCA1 and nascent HDL biogenesis | |
| CA2486127C (en) | Method of treating dyslipidemic disorders | |
| Barylski et al. | Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality | |
| AU2012214672B2 (en) | Lipoprotein complexes and manufacturing and uses thereof | |
| MX2012014928A (es) | Una formulacion de lipoproteina de alta densidad reconstituida y metodo de produccion de la misma. | |
| JP2008534487A5 (enExample) | ||
| Numata et al. | Nanodiscs as a therapeutic delivery agent: inhibition of respiratory syncytial virus infection in the lung | |
| Sviridov et al. | High-density lipoprotein mimetics: promises and challenges | |
| JP2017528437A5 (enExample) | ||
| JP5960990B2 (ja) | 組み換え技術によって製造された第ｖｉｉｉ因子のための新規な保護組成物 | |
| JP2016026186A (ja) | テトラネクチン−アポリポタンパク質ａ−ｉ、それを含有する脂質粒子及びその使用 | |
| Getz et al. | Apoprotein AI mimetic peptides and their potential anti-atherogenic mechanisms of action | |
| EP2688584A1 (en) | Pegylated human hdl particle and process for production thereof | |
| JP2015500840A5 (enExample) | ||
| RU2014129505A (ru) | Схема дозирования для составов аполипопротеина | |
| Wang et al. | Reconstituted high density lipoprotein-based nanoparticles: an overview of applications in regenerative medicine, preparation, evaluation and future trends | |
| Vucic et al. | Recombinant high-density lipoprotein formulations | |
| WO2017120568A1 (en) | Apoe mimetic peptide compositions | |
| JP6207507B2 (ja) | 短縮されたテトラネクチン−アポリポプロテインａ−ｉ融合タンパク質、それを含む脂質粒子、及びその使用 | |
| Du | Nanoparticles Targeting at Inflammation Site | |
| NZ614405A (en) | A reconstituted high density lipoprotein formulation and production method thereof | |
| HK1193616A (en) | Shortened tetranectin-apolipoprotein a-i fusion protein, a lipid particle containing it, and uses thereof | |
| HK1181668A (en) | Tetranectin-apolipoprotein a-i, lipid particles containing it and its use |